Dear ,

In the current issue of the OncoWuXi Newsletter, we share with you the update on our service and newly established capabilities.

OncoWuXi Newsletter will continue to keep you up to date with our recent progress in cancer research. As a part of the WuXi Biology, our top-notch Oncology-Immunology team is dedicated to providing end-to-end services and solutions to support the ever-changing research needs of cancer and autoimmune diseases, and is your ideal partner for enabling technological breakthrough and accelerating cancer drug discovery.
Translational Oncology
NanoString Platform for Research and Translational Applications

(1)  Use the commercial or customized NanoString panels to perform (on FFPE samples or small amounts of starting material, without amplification):
  • Identification of differentially expressed genes in tumor and paracancer tissues
  • Identification of CT antigen
  • T cell function gene set analysis
  • Cell type profiling
  • Functional enrichment analysis
(2)  Case studies:
  • Exploration on responses of animal models to anti-tumor drugs at transcriptional level
  • Time-ordered immune responses assessment in syngeneic tumor model after treatment

Genetically Engineered Animal Model
Siglec-15 KO animal model in C57BL/6 mice with CRISPR/Cas9 mediated genome editing, facilitating immunotherapy research targeting Siglec-15.

Cancer Vaccine Discovery Platform

(1)  Tumor neo-antigen prediction and in vivo immunogenicity validation

(2)  Determine and validate immunogenicity of peptides using ELISpot in vitro assay

(3)  Validate immunogenicity of OVA mRNA vaccine using ELISpot in vitro assay

(4)  In vivo validation of peptide vaccine using B16F10 or CT26 tumor model

(5) In vivo validation of DC vaccine using B16F10 tumor model

Targeted Oncology
VEGF-VEGFR Related In Vivo Models

(1)  VEGF-VEGFR related CDX models
  • HCT-15, SW620, LS174T, and HT-29 colorectal cancer CDX models, tested with Avastin or Regorafenib
  • Huh7, BEL-7404, Hep-3B, and JHH-7 liver cancer CDX models, tested with Avastin and Sorafenib
  • Calu-6, A549, NCI-H520, PC-9, and NCI-H358 NSCLC CDX models, tested with Nintedanib, Axitinib, Sunitinib, Apatinib or Avastin
  • 786-O and ACHN renal cancer CDX models, tested with Sorafenib, Sunitinib and Avastin
  • MCF-7 breast cancer and U87MG glioblastoma CDX models, tested with Avastin
  • NCI-H69 SCLC CDX model, tested with Anlotinib
  • MKN-45 gastric cancer CDX model, tested with Sunitinib and Apatinib
  • FTC-238 thyroid cancer CDX model, tested with Lenvatinib

(2)  VEGF-VEGFR related PDX models
  • 25 HCC PDX models, tested with Sorafenib, Regorafenib, Lenvatinib or other TKIs
  • 8 cholangiocarcinoma PDX models, tested with Cabozantinib
  • Other PDX models, tested with Sorafenib, Avastin, Cabozantinib or Pazopanib

We sincerely appreciate your interest, time and support, and would like to hear your feedback so that we can continuously improve our service. Please don't hesitate to email us if you have any questions, suggestions or concerns. 
Best regards,
WuXi AppTec OncoWuXi Team